EU4 Health Program (EU4H)
23 July 2021
Covid doubles eating disorders in young Aragonese
26 July 2021
The Japanese company Shionogi has begun human testing of its pill, which would be a daily dose, and which seeks to neutralize the virus within days once a person becomes infected.
The race between several pharmaceutical to develop a treatment in the form of a pill against covid-19 is accelerating, with a Japanese firm starting clinical trials and joining giants likeo Pfizer and MSD (Merck Sharp & Dohme).
The Japanese company Shionogi has begun human testing of its pill, which would be a daily dose, and that seeks to neutralize the virus within days once a person becomes infected, according to The Wall Street Journal this Sunday.
Shionogi, who in the past has had success among others with a drug to reduce cholesterol, It is still behind Pfizer and MSD, which have more advanced studies on this type of treatment.
These pills for covid-19 are designed for patients to use when they have mild symptoms and are in their homes, unlike the treatments that have given the most results so far, such as redevive, which have to be administered in hospitals and are generally reserved for more serious patients.
With the focus especially on vaccines, During the last year there has not been much progress in this area and the usual treatments have hardly changed
In the case of Pfizer, the company has said that its pill, which would be taken twice a day and is similar in design to Shionogi's, could be ready to hit the market as soon as this year.
MSD, meanwhile, is using a formula studied years ago as a possible response to Ebola and has said that for now it has been proven effective in reducing the viral load of covid-19 patients and could reduce the risk of hospitalization.
